FDA Bans US Import of Piston Syringes from Thailand Site

January 27, 2017

On Wednesday, January 25th, the FDA issued Import Alert 89-17, which banned the import of Nipro’s piston syringes (with luer lock tip or catheter tip) into the US from the company’s Thailand location.

As noted in the Agency’s alert, section 501(c) of the Federal Food, Drug, & Cosmetic (FD&C) Act states that “a device is adulterated if its quality falls below that which it purports or is represented to possess.”  Furthermore, FDA states that it “has collected and analyzed samples of various medical devices which have not met the quality level that they purported or were represented to possess, in accordance with acceptance criteria in a standard or in a manufacturer's Quality System (QS) Regulation acceptance procedure. Devices which do not meet their own established medical device specifications or the quality level they were represented to meet could result in a potential health risk to the end user.”

According to a recent article from RAPS, Nipro has not responded to their request for a comment.

For additional information, view the FDA’s full import alert.

Are you in danger of having a product barred from being imported into the US?  Do you want to prevent this type of situation from happening to your company?  We can help ensure your company and products are compliant with all FDA regulations and requirements.  To learn more about our qualifications and capabilities, contact us today.


Small array of different types of pills and tablets

October 18, 2016

Top Ten FDA Guidance Documents That You Should Know

There are a number of laws, regulations, and guidance documents ruling the pharmaceutical and biotechnology industries. Laws are passed by Congress and must be followed by the FDA. The Agency then...

January 5, 2016

Best Practices for FDA Communication with IND Sponsors

On December 9, 2015, the FDA released a draft guidance entitled, “Best Practices for Communication Between IND Sponsors and FDA During Drug Development.” The guidance attempts to promote timely,...

January 26, 2017

FDA Makes Critical Data Update to the Orange Book

On Wednesday, January 25th, the FDA unveiled a critical data update to Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the “Orange Book.” According to the...